Lugano, Schweiz (ots) - Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary , Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS ...
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
Lugano, Switzerland (ots) - Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC) Helsinn Group is pleased to announce that ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - Medical oncologists have a vital role to play in cancer care, particularly as treatments become ever more complex, a new position statement from the European Society for Medical Oncology says (http://www.presseportal.ch/go2/new_position_statement ). Medical oncologists are specialist cancer physicians ...
Lugano, Switzerland/Woodcliff Lake, NJ, USA (ots) - Seeking indication for prevention of chemotherapy-induced nausea and vomiting Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigational ...
Lugano, Switzerland - Beijing, PRC (ots) - Helsinn Group, the independent, privately-owned, Swiss pharmaceutical company, with a worldwide presence built over 35 years, lands in China. Helsinn's Representative Office was officially inaugurated in Beijing, PRC yesterday. With headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - A ground-breaking international survey published today, shows that more than half of the world's population live in countries where regulations aiming to stem drug misuse leave patients without access to opioid medicines for managing cancer pain. The results from the Global Opioid Policy Initiative ...
Lugano, Switzerland (ots) - Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland Swiss-based Helsinn group has granted Chugai ...
Lugano, Switzerland (ots) - The Swiss Helsinn Group announced today the formation of a sales organization in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization of 20 people has been engaged throughout the United States. The new oncology sales representatives will be working via a co-detailing agreement for Aloxi® (palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. The ...
MESA Medical Equipment Solutions and Applications
Lugano, Switzerland and Mikolow, Poland (ots) - Culminating from a three-year relationship involving operational synergies for diagnostic imaging service and equipment solutions, two of the largest multi-vendor service providers in Europe: Pan-European, Swiss-based Medical Equipment Solutions and Applications (MESA) ...
Lugano, Switzerland and Barcelona, Spain (ots) - The Swiss pharmaceutical group Helsinn and the Spanish company, Advancell, Advanced In Vitro Cell Technologies, SA, today announced a partnering agreement for the development and worldwide commercialization of ATH008, a new topical product for the prevention and/or ...
Lugano, Switzerland & Copenhagen, Denmark (ots) - The decision follows promising findings from a Phase IIa Proof-of-Concept study. Helsinn is planning a Phase IIb study with elsiglutide, and study activities are expected to start in H2 2013. The Swiss pharmaceutical group Helsinn, a leading player in the cancer ...
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and ...
Lugano/Glattbrugg, Switzerland (ots) - Helsinn Healthcare SA and Vifor Pharma, announced that the companies have entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination, a Helsinn product currently in the development stage for the treatment of ...
Lugano, Switzerland/Raleigh, N.C. (ots) - The Swiss pharmaceutical Helsinn Group, a leading player in the cancer supportive care arena, announced today that DARA BioSciences, Inc., a U.S. specialty pharmaceutical company focused on oncology and oncology supportive care products, has launched Gelclair® into the U.S. ...
Lugano, Switzerland (ots) - Helsinn Group has entered into a new partnership with Healthcare Businesswomen's Association (HBA). HBA is the premier catalyst for the leadership development of women, to further the advancement and impact of women in healthcare worldwide. HBA accomplishes this by providing educational opportunities to develop cutting-edge industry ...
Lugano, Switzerland and Mexico City, Mexico (ots) - Stendhal strengthens its pipeline of in-licensed specialty drug products by signing a Distribution and License Agreement with Helsinn Group for an innovative phase III ghrelin receptor agonist. Swiss pharmaceutical Helsinn Group has granted Latin American specialty ...
Lugano (ots) - Helsinn Group is pleased to announce that tomorrow (Tuesday, January 8th, 2013) at 9am Pacific Standard Time (18:00 Swiss time), Dr. Riccardo Braglia, Helsinn Group CEO, will present an overview of the Helsinn group, its products and corporate goals at the 31st Annual J.P. Morgan Healthcare Conference, San Francisco. Dr. Braglia's presentation will be ...
Lugano, Switzerland (ots) - The Swiss pharmaceutical Helsinn Group announces today that Taiho Pharmaceutical Co. Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist (5- HT3 RA) palonosetron, has launched on the national market the 0.75mg infusion bag formulation of palonosetron hydrochloride (Aloxi®). The infusion bag is an additional formulation to the 0.75mg injectable form already marketed ...
Lugano (ots) - Helsinn Group announces that it has signed an agreement with the Conquer Cancer Foundation of the American Society of Clinical Oncology to provide long-term financial support for CancerLinQ, a multi-phase initiative to build a rapid learning system in oncology. Helsinn supports the Foundation's ...
Lugano, Switzerland (ots) - ESASO, the European School for Advanced Studies in Ophthalmology, has opened the 12th AMD and Retina Congress in Prague. Following on from the 11th congress in Lisbon, which covered the whole spectrum of retinopathy, this year's meeting in the Czech Republic takes a significant step ...
Lugano, Switzerland and Melbourne, Australia (ots) - Helsinn Healthcare SA and STA reinforce their Cancer Supportive Care Alliance in Australia and New Zealand with a Distribution and License Agreement for the innovative phase III ghrelin receptor agonist Melbourne biopharmaceutical company Specialised Therapeutics ...
Lugano, Switzerland & Vienna, Austria (ots) - New data presented at the 2012 meeting of the European Society of Medical Oncology (ESMO) in Vienna show antiemetic efficacy maintained across the chemotherapy cycles and a positive safety profile The oral formulation of palonosetron, the second generation 5-HT3 receptor ...
Lugano (ots) - Helsinn Group announces that on September 18th it has signed a license agreement with CJ CheilJedang, Korea for Helsinn's new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV). The agreement covers the exclusive license and distribution rights for a ...
Lugano, Switzerland / Raleigh, N.C., USA (ots) - Gelclair® Strengthens DARA's Growing Portfolio of In-licensed Oncology and Oncology Supportive Care Products The Helsinn Group of Switzerland announced today that it has entered into an exclusive agreement with DARA BioSciences, Inc. (Nasdaq: DARA) for U.S. ...
Lugano, Switzerland (ots) - Starting July 1st the Swiss Group has become Gold sponsor of the Sharing Progress in Cancer Care (SPCC) Programme Through its support to the Sharing Progress in Cancer Care (SPCC) Programme, Helsinn Group starts to actively collaborate with the European School of Oncology (ESO) in promoting education in oncology, with special attention to cancer supportive care. SPPC is a collaborative ...
Lugano (ots) - Considerable inflow of net new money: CHF 6.7 billion (+8.8%). CHF 77.7 billion in assets under management - Considerable inflow of net new money: CHF 6.7 billion (+8.8%). Assets under management stood at CHF 77.7 billion, up 1.9% despite the appreciation of the Swiss franc and the continuing negative trend on the financial markets - Continued successful expansion in fast-growing markets: Asia, Latin ...
Lugano, Switerland (ots) - The Company has entered the Phase III clinical program for both its investigational medications anamorelin, in non-small cell lung cancer-associated anorexia/cachexia, and netupitant + palonosetron oral fixed-dose combination in chemotherapy-induced nausea and vomiting (CINV) Helsinn, the Swiss pharmaceutical Group, global leader in the segment of the prevention of chemotherapy-induced nausea ...
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and ...